Figure 1.

Competition between human fVIIa and the mfVIIasm immunoconjugate for binding to TF2 cells. The assays were done by fluorescence-activated cell sorting. Curve A: Control without fVIIa or mfVIIasm immunoconjugate. Curve B: Equimolar mixture of fVIIa and mfVIIasm immunoconjugate (25 nM each). Curve C: 10× molar excess of fVIIa to mfVIIasm immunoconjugate (250 nM/25 nM). Curve D: mfVIIasm immunoconjugate only (25 nM).